One of the crucial challenges in the clinical management of cancer is the resistance to chemotherapeutics. We recently demonstrated that the Hedgehog receptor Patched, which is overexpressed in many recurrent and metastatic cancers, is a multidrug transporter for chemotherapeutic agents such as doxorubicin. The present work provides evidences that Patched is expressed in adrenocortical carcinoma (ACC) patients, and is a major player of the doxorubicin efflux and the doxorubicin resistance in the human ACC cell line H295R. We discovered that methiothepin inhibits the doxorubicin efflux activity of Patched. This drug-like molecule enhances the cytotoxic, pro-apoptotic, antiproliferative and anticlonogenic effects of doxorubicin on ACC cells which endogenously overexpress Patched, and thereby mitigates the resistance of these cancer cells to doxorubicin. Moreover, we report that in mice the combination of methiothepin with doxorubicin prevents the development of xenografted ACC tumors more efficiently than doxorubicin alone by enhancing the accumulation of doxorubicin specifically in tumors without obvious undesirable side effects. Our results suggest that the use of an inhibitor of Patched drug efflux such as methiothepin in combination with doxorubicin could be a promising therapeutic option for adrenocortical carcinoma, and most likely also for other Patched-expressing cancers.
Introduction
Despite the major progresses in biomedical research and the development of novel therapeutic strategies, cancer remains among the dominant causes of death worldwide. One of the crucial challenges in the clinical management of cancer is primary (intrinsic) and secondary (acquired) resistance to both conventional and targeted chemotherapeutics. Multidrug resistance (MDR) has been intensively studied, and one of the most prominent mechanisms underlying MDR is overexpression of members of the family of ATP-binding cassette (ABC) transporters. 1, 2 These transporters use energy derived substrates (endogenous toxicants and xenobiotics and also chemotherapeutic agents) across biological membranes against a concentration gradient. Since the discovery that the overexpression of ABC transporters in cancer cells can mediate resistance to anti-cancer drugs, research has been directed toward developing compounds that inhibit the efflux activity of ABC transporters and increase classical chemotherapy efficacy. However, to date, the Food and Drug Administration (FDA) has not approved the use of any ABC transporter inhibitor due to toxicity issues. 3, 4 It has long been postulated that the multidrug efflux transporter P-glycoprotein (P-gp/ ABCB1/MDR1) mediates the main mechanism of resistance within cancer cells; 5 however, we recently showed that the Hedgehog (Hh) receptor Patched, which is overexpressed in many recurrent and metastatic cancers, pumps chemotherapeutic agents such as doxorubicin (dxr) out of cancer cells thereby also contributing to chemotherapy resistance. 6 The
Hh signaling pathway controls cell differentiation and proliferation. It plays a crucial role in embryonic development, in stem cell homeostasis and tissue regeneration in the adult. 7 However, Hh signaling is also involved in cancer development, progression and metastasis. Indeed, aberrant activation of Hh signaling has been observed in many aggressive cancers, 8 in particular in cells exhibiting resistance to chemotherapy such as cancer stem cells or tumor-initiating cells. 9 The Hh receptor Patched, whose expression is induced upon activation of the Hh pathway, is overexpressed in many cancers such as lung, breast, prostate, ovary, colon, brain, melanoma 8, 10, 11 and myeloid leukemia 12, 13 (see the Human Protein Atlas website http://www.proteinatlas.org/ ENSG00000185920-PTCH1/cancer). Recent studies even suggested Patched as an early marker of gastric and thyroid cancers. 14, 15 The discovery that Patched has a drug efflux activity led us to propose Patched as a new target to enhance the efficiency of classical chemotherapeutic treatments and to decrease the risk of recurrence and metastasis. We then developed screening tests to identify molecules able to inhibit the drug efflux activity of Patched. 16 Based on this screen, we have shown that a natural compound purified from a marine sponge increased the cytotoxicity of dxr in vitro on human melanoma cells which endogenously overexpress Patched. This compound was the first inhibitor of Patched dxr efflux activity to be described. 17 Here, we report the discovery of a new inhibitor of Patched drug efflux activity identified by screening of a collection of 1,200 small molecules. We show that methiothepin (also named P375 hereafter), a well-known non-selective 5-HT transporter antagonist, enhances dxr efficiency both in vitro and in vivo against adrenocortical carcinoma (ACC) cells in which Patched is endogenously expressed and strongly contributes to the resistance to doxorubicin. These results provide a proof of concept demonstration that the combination of dxr with a Patched drug efflux inhibitor can significantly improve therapeutic treatment of adrenocortical carcinoma.
Materials and Methods

Chemical and biological material
Methiothepin maleate (P375) was purchased from Santa Cruz: CAS number: 20229-30-5; MW: 472.62; molecular formula: C 20 H 24 N 2 S 2 .C 4 H 4 O 4 . Doxorubicin hydrochloride, Hoechst 33342, cisplatin and temozolomide were purchased from Sigma-Aldrich, Lyon, France. PSC833 was purchased from Tocris.
K699 Saccharomyces cerevisiae yeast strain (Mata, ura3 and leu 2-3, kindly donated by R. Arkowitz) was transformed with pYEP-hPtc-MAP (human Patched) or pYEPmMyo-MAP (control) expression vector and grown at 188C until OD 600 5-7 as described. 18 The human adrenocortical carcinoma cell line H295R was cultured in DMEM/F12 supplemented with 2% NuSerum (BD), 1% ITS1 (BD) and penicillin/streptomycin (Invitrogen, USA) at 378C in a 5% CO 2 /95% air water-saturated atmosphere. H295RdxrR were obtained by adding increasing concentrations of dxr until 0.2 mM in the culture medium during 6 months.
MUC-1 cells were established and cultured as described in ref. 19 .
The human colorectal carcinoma (HCT116), breast adenocarcinoma (MCF7) and melanoma (A375) cell lines were purchased from ATCC, and cultured in DMEM medium supplemented with 10% fetal bovine serum and penicillin/ streptomycin (Invitrogen, US) at 378C in a 5% CO 2 /95% air water-saturated atmosphere.
Effect of molecules on the resistance to doxorubicin of yeast expressing Patched
The yeast screening campaign was carried out as described in ref. 16 . S. cerevisiae expressing human Patched were grown in 10 mL of minimal medium (supplemented with 2% of What's new? Multidrug resistance to chemotherapy can develop when membrane proteins pump drugs out of cancer cells faster than the drugs can kill them. In this study, the authors found that a compound called methiothepin inhibits drug efflux that is mediated by a protein called Patched. They then found that adding methiothepin to doxorubicin is more effective in blocking tumor growth in vivo than doxorubicin alone. These results suggest that methiothepin may be a valuable adjunct to chemotherapy in cancers that overexpress Patched.
glucose and aminoacid cocktail without leucine) at 308C. At OD 600 between 5 and 7, yeast were diluted for a preculture in the same medium to OD 600 5 1-2. Yeast were then diluted in rich medium containing 2% glucose in 96-well plates in triplicate. 10 mM of each molecule were added in all wells, and chemotherapeutic agent was added in half of the wells (dxr was added at 10 mM final concentration). Plates were incubated at 188C on a shaker at 1,250 rpm (microtiter plate shaker SSL5 Stuart) and absorbance at 600 nm was recorded for about 72 hr.
Effect of P375 on doxorubicin cytotoxicity
Cells were seeded in 96-well plates in triplicate and grown in medium to achieve 70-80% confluence. Medium was then removed and replaced with 100 mL/well of complete medium containing P375 or DMSO as control. After 2 hr, 100 mL of complete medium containing serial dilutions of dxr was added. For P375 IC50 calculation, cells were incubated with serial dilutions of P375 2 hr before addition of medium containing 2 mM of dxr or PBS. Plates were incubated at 378C and 5% CO 2 . After 24 or 48 hr, cells were incubated 3 hr at 378C with 100 mL/well neutral red (NR) solution (50 mg/mL in medium) or MTT (Sigma-Aldrich) following the manufacturer's protocols. Measurements were made in microplate readers (Multiskan Go Microplate Spectrophotometer from Thermo Scientific (US) and SPECTRA from Tecan (M€ annedorf, Switzerland)). IC50 was defined as the concentration that resulted in a 50% decrease in the number of live cells, and IC50 values were calculated using GraphPad Prism 6 software.
Isobologram analysis for determination of synergy
Isobologram analysis was performed as described in refs. 20,21. To establish the mode of interaction between dxr and P375, the cells were treated with different concentrations of dxr and P375. Analysis was done on the basis of dose-response curves of cell viability treated with dxr or P375 alone or their combination for 48 hr, and isobolograms were created using Compusyn Software (Version 1.0 downloaded from www.combosyn. com, 22 ). These equations provide the theoretical basis for the combination index (CI)-isobologram equation that allows quantitative determination of drug interactions, where CI < 1 (below the diagonal), 5 1 (diagonal) and > 1 (above the diagonal) indicate synergism, additive effect and antagonism, respectively. Dose-reduction index (DRI) is reported.
Apoptosis measurements
Cells were seeded at a density of 7,000 cells per well in a 96-well white polystyrene plate (Falcon Corning 96 Well Plate) in triplicate and cultured overnight at 378C and 5% CO 2 . After removal of the medium, cells were treated 48 hr with medium alone or with medium containing dxr alone, P375 alone or dxr and P375 together. Quantification of caspase 3/7 activity was performed using the luminescent assay CaspaseGlo 3/7 (Promega Charbonnières-les-Bains, France) and a luminometer (Glomax 96 Microplate Luminometer Promega, France) following the manufacturer's protocol.
Proliferation
Cells were seeded at a density of 5,000 cells per well in 96-well plates (Falcon 96 Well Clear Microplate, Corning, Inc., New York, US) in triplicate and grown for 24 hr at 378C and 5% CO 2 . After removal of the medium, cells were treated with medium containing serial dilutions of dxr in the presence or the absence of P375. DMSO was added in control wells. After 7 days at 378C and 5% CO 2 , NR test was used for quantification of living cells. IC50 was defined as the concentration that resulted in a 50% decrease in the number of live cells, and IC50 values were calculated using GraphPad Prism 6 software.
Clone formation
Cells were seeded in 24-well plates (Falcon from Corning, Inc., NY, US) at a density of 5,000 cells per well in triplicate, treated with DMSO as control, P375 alone, dxr alone or a combination of P375 and dxr, and incubated at 378C and 5% CO 2 . After 7 days, 500 lL of medium containing the respective molecules was added to the wells. After 14 days cells were fixed with 4% PFA and incubated with 0.4% crystal violet. After 1 hr, cells were washed quickly with PBS and pictures of the wells were taken. Cells were solubilized with 1% SDS and absorbance was read in a microplate reader at 550 nm (Multiskan Go Microplate Spectrophotometer, Thermo Scientific). 
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) or control (medium GC) siRNA oligos (Invitrogen) using the Amaxa nucleofection technique (Lonza, Basel, Switzerland), as described. 24 5 3 10 6 cells per condition were electroporated with 400 pmol siRNA following the manufacturer's protocol, then seeded in 24-well plates and incubated at 378C and 5% CO 2 during 16 hr before western blotting and dxr efflux measurements.
SDS-PAGE and western blotting
Total RIPA (Radioimmunoprecipitation assay buffer) extracts from cells were prepared. Protein concentrations were determined by the DC Protein Assay (Biorad, Roanne, France). Samples (50-80 mg) were separated on 7.5% SDS-PAGE and transferred to nitrocellulose membranes (Amersham, Piscataway, US) using standard techniques. 
Doxorubicin efflux
Dxr efflux measurements were carried out as described in ref. 17 . On yeast: yeast expressing Patched (hPtc) or control yeast were grown to an OD 600 of 5, centrifuged, washed with cold water, resuspended at an OD 600 of 10 in HEPES-NaOH buffer (pH 7.0) supplemented with 5 mM 2-deoxy-D-glucose, and incubated with 10 mM dxr for 2 hr at 48C in the cold room on a rotating wheel protected from light. Yeast were centrifuged and the supernatant was removed. One sample was immediately fixed with 4% PFA for dxr loading control. The other samples were resuspended in HEPES-NaOH buffer (pH 7.0) containing 5 mM 2-deoxy-D-glucose supplemented with DMSO, 10 mM P375 or 2.5 mM PSC833 and incubated 10 min at 208C with gentle shaking in a Benchmark Multitherm shaker (Innova 2000, New Brunswick Scientific CO, Inc US) protected from light. Samples were centrifuged for 1 min at 18,000g, supernatants were removed and yeast were fixed with 4% PFA. 10 mL of each sample were deposited on a coverslip and mounted in SlowFade Gold antifade reagent with DAPI (Invitrogen).
On cells: cells were seeded on coverslips in 24-well plates and allowed to grow to 80% confluence. Coverslips were incubated at 378C and 5% CO 2 with 10 lM dxr in physiological buffer (140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgSO 4 , 5 mM glucose, 20 mM HEPES, pH 7.4). After 2 hr, three coverslips were immediately fixed 10 min with 4% PFA for dxr loading control, rapidly washed with PBS and mounted in SlowFade Gold antifade reagent with DAPI (Invitrogen). The other coverslips (a triplicate per condition) were incubated with physiological buffer supplemented with DMSO, 10 mM P375 or PSC833 for 30 min under gentle shaking at room temperature and protected from light. They were then immediately fixed with 4% PFA, washed and mounted as described above.
Images for dxr quantification were acquired with a Zeiss Axioplan 2 fluorescence microscope coupled to a digital charge-coupled device camera using a 633 objective for yeast or a 403/1.3 Plan NeoFluar objective for cells and filters for Alexa 594. Dxr fluorescence was quantified using ImageJ software. Sampling of yeast/cells was performed randomly. About 100 yeast/cells (from three wells) were scored per condition per experiment.
On tumors and heart slides: images for dxr quantification were acquired on slides with a Zeiss Axioplan 2 fluorescence microscope coupled to a digital charge-coupled device camera using a 103/1.5 Plan NeoFluar objective and a filter for Alexa 594. Dxr fluorescence was quantified using ImageJ software.
Pharmacokinetic study
P375 was formulated at 0.4 mg/mL (for IV) and 1 mg/mL (for PO) in DMSO/Solutol V R HS15/phosphate buffered saline (PBS) (5/5/90, v/v/v and administered to non-fasted male ICR mice (weighing 20-30 g) intravenously (IV) at the dosing volume of 5 mL/kg and orally (PO) at 10 mL/kg. Serial plasma samples were harvested via the facial vein at 3, 10, 30, 60, 120, 240, 360 and 1,440 min post dosing for IV group, and at 10, 30, 60, 120, 240, 360, 480 and 1,440 min for PO Group (three mice per time point). Plasma was prepared from blood aliquots (50 lL) collected via facial vein sampling from individual mice, in tubes coated with K 2 EDTA, mixed gently, then kept on ice and centrifuged at 2,500g for 15 min at 48C, within 1 hr of collection. For control animals, blood was collected by cardiac puncture. The plasma samples were processed using acetonitrile precipitation and analyzed by LC-MS/MS. A plasma calibration curve was generated. Aliquots of drug-free plasma were spiked with the test compound at the specified concentration levels. The spiked plasma samples were processed together with the unknown plasma samples using the same procedure. The processed plasma samples were stored at 2708C until LC-MS/MS analysis, at which time peak areas were recorded, and the concentrations of the test compound in the unknown plasma samples were determined using the respective calibration curve. Plots of plasma concentration vs. time were constructed and the pharmacokinetic parameters of P375 after IV and PO dosing were obtained from the analysis of the plasma data.
Animal experiments
For therapeutic experiments female athymic NMRI nu/nu mice (6-8 weeks) were purchased from Charles River (Sulzfeld, Germany) and housed under pathogen-free conditions. All experiments were carried out following protocols approved by the Regierung von Oberbayern and in accordance with the German guidelines for animal studies. H295R xenografts were induced as described before. 25, 26 For shortterm experiments, tumor-bearing mice (n 5 4-5) were treated with one therapeutic cycle which consisted of either liposomal doxorubicin (lipdxr) (6 mg/kg body weight, intravenously on Days 4 and 10), P375 (2 mg/kg body weight, intraperitoneally on Days 1-11) or a combination of lipdxr and P375 (P375: 2 mg/kg body weight intraperitoneally on Days 1-11 plus lipdxr 6 mg/kg body weight intravenously on Days 4 and 10). 48 hr after the last administration, the shortterm study was terminated and animals sacrificed. Afterwards, tumors were excised and subsequently paraffin embedded. The slide preparation of these paraffin embedded tissues as well as the quantification of the number of apoptotic tumor cells, using the colorimetric DeadEND TUNEL System (Promega, Mannheim, Germany), were performed as described elsewhere. 25 For long-term therapeutic protocols, mice (n 5 7-8) received two treatment cycles with a therapyfree interval of 6 days in between. Animals were monitored daily and tumor sizes measured every second day (as tumor length 3 width [cm 2 ]). At Day 40 after tumor induction, when first tumors reached a longest tumor diameter of 1.5 cm, the long-term therapeutic study was terminated, tumors and hearts were excised and subsequently paraffin embedded.
Statistical analysis
All results represent at least three independent replications. Data are shown as mean value 6 SEM. Statistical analyses were performed with Prism 6 software (GraphPad) using one-way analysis of variance (ANOVA) followed by Bonferroni's or Dunnett's (TUNEL staining) Multiple Comparison Tests. For the long-term therapeutic experiments a two-way repeated measures ANOVA was applied.
Results
Methiothepin inhibits the resistance of yeast expressing Patched to doxorubicin
In a previous study, we reported that the expression of human Patched allowed yeast to grow in the presence of a concentration of doxorubicin (dxr) that inhibits the growth of control yeast, indicating that Patched confers resistance to dxr. 6 From these results, we developed a screening test in 96-well plates to identify compounds capable of inhibiting the resistance to dxr of yeast expressing human Patched. 16 1,200 drug molecules from the Prestwick Chemical library were tested at a final concentration of 10 mM on yeast expressing Patched in a medium supplemented or not with dxr. We observed that the compound P375, which corresponds to methiothepin maleate, a small molecule known as a non-selective 5-HT receptor antagonist, significantly inhibited the growth of yeast expressing Patched in the presence of dxr in contrast to the majority of the molecules tested such as P298 that had no effect (Fig. 1a) .
Notably, P375 had no effect on the growth of yeast expressing Patched in the absence of dxr and did not inhibit the growth of control yeast in the presence of smaller amounts of dxr (Fig.  1a) suggesting that this molecule inhibits specifically dxr resistance conferred by Patched activity.
Methiothepin inhibits doxorubicin efflux from yeast expressing Patched
We took advantage of the natural fluorescence properties of dxr 27 to carry out dxr efflux measurements, and tested the effect of P375 on dxr efflux as described before. 17 2-Deoxy-Dglucose was added in buffer during dxr loading and efflux to de-energize yeast and inhibit ATP-binding cassette (ABC) transporters which also contribute to dxr efflux in yeast. This enabled us to selectively study ATP independent efflux activity. Dxr fluorescence measured in yeast expressing Patched after efflux in buffer containing DMSO (P375 solvant) was significantly lower than that measured in control yeast, consistently with the dxr efflux activity of Patched already described 6 ( Fig. 1b left panel) . Dxr fluorescence in yeast expressing Patched was significantly higher when P375 was present in the efflux buffer while this molecule had no significant effect on the dxr fluorescence of control yeast (Fig. 1b  right panel) , indicating that P375 specifically inhibited Patched dxr efflux activity. Note that the P-glycoprotein (Pgp) inhibitor PSC833 had no significant effect on the dxr efflux activity of Patched.
Adrenocortical carcinoma as a paradigm of Patched-expressing cancers
Adrenocortical carcinoma (ACC) is a rare cancer which presents strong resistance to the best available treatment composed of a mixture of chemotherapeutic agents (etoposide, doxorubicin and cisplatin) combined with the adrenolytic substance mitotane (EDP-M). [28] [29] [30] The expression of Hh signaling components was analyzed in tissue samples of 70 ACC patients. IHC analysis showed that the Hh receptor Patched and the Hh signaling receptor Smoothened were expressed at the protein level in ACC tumor tissues (Fig. 2a) , and were positively correlated (Spearman's R 5 0.38 p 5 0.002). Median H-score values were 130 for Patched and 90 for Smoothened. Intensity and distribution was highly heterogeneous among individual tumors (Fig. 2b) . As shown in Figure 2c , Patched is also strongly expressed in the ACC cell line H295R which was initially isolated from a patient diagnosed with ACC. 31, 32 Interestingly, Patched expression was found to be significantly lower in the MUC-1 cell line which had recently been established from an ACC metastasis obtained from a patient with a primary diagnosis of ACC. 19 
Methiothepin increases the cytotoxicity of doxorubicin on adrenocortical carcinoma cells expressing Patched
As dxr is used as a standard compound of therapeutic regiments for patients with advanced ACC, we decided to test the effect of P375 on dxr cytotoxicity using the two available Cancer Therapy and Prevention human ACC cell lines H295R and MUC-1. Specifically, cells were treated separately with increasing concentrations of P375 in the presence of 2 mM dxr during 48 hr before cell viability measurement. We observed that P375 significantly increased the cytotoxicity of dxr against the H295R cell line in a dose-dependent manner (Fig. 3a left panel) , while this molecule had no effect on the cytotoxicity of dxr against the MUC-1 cell line (Fig. 3a right panel) . Remarkably, these results indicate, that this molecule seems to increase dxr efficiency only on cells overexpressing Patched.
Accordingly, we decided to use the H295R cell line to characterize the effect of P375 on dxr cytotoxicity. Cells were treated with increasing concentrations of dxr, with or without P375, during 48 hr before assessment of cell viability. Results showed that P375 induced a significant decrease in the dxr-IC50 on H295R cells (>6 times) (Fig. 3b) without affecting Patched protein levels or Hedgehog signaling (Supporting Information Fig. S1 ). We observed the same effect of P375 on cells rendered resistant to dxr (H295R Dxr R) (Fig. 3c) . Interestingly, these dxr resistant cells exhibited an increased level of Patched expression, suggesting that Patched upregulation was the cause for their resistance (Fig. 3d ). These results demonstrate that P375 strongly enhanced the efficiency of dxr on ACC cells expressing Patched. The isobologram Yeast expressing wild-type Patched and control yeast were incubated with dxr for 2 hr and fixed for dxr loading control, or resuspended in buffer supplemented with DMSO, 10 mM P375 or 2.5 mM PSC833 for 10 min and fixed. Histograms represent the intracellular dxr fluorescence quantification which was carried out using Image J software on >100 yeast from three different fields for each condition on three independent experiments. Data are represented as mean 6 SEM and were analyzed using ANOVA multiple comparison test and Bonferroni correction. Significance is attained at p < 0.05 (*) (****p < 0.0005). [Color figure can be viewed at wileyonlinelibrary.com] analysis clearly showed that dxr and P375 exhibit significant synergism as demonstrated by cooperativity indices of 1 (Supporting Information Fig. S2 ). We also observed that P375 increased the efficiency of cisplatin, of etoposide and of the clinical gold standard EDP-M treatment (Supporting Information Fig. S3 ). Dose-responses of P375 on cell viability were performed providing IC50 values of about 3 mM in the presence of 2 mM dxr, a dose which has a very low cytotoxicity alone (about 15%) (Fig. 3e) .
Methiothepin increases the pro-apoptotic, antiproliferative and anti-clonogenic effects of doxorubicin
In agreement with the results of cytotoxicity, apoptosis experiments based on caspase 3/7 activation measurements indicated that the addition of P375 to dxr treatment significantly increased the percentage of apoptotic cells (Fig. 4a) . We also observed that the presence of P375 in the culture medium significantly increased the anti-proliferative effect of dxr on H295R cells, dxr-IC50 on cell proliferation being reduced nearly 10 times with 2 mM of P375 (Fig. 4b) . Moreover, the combination of dxr and P375 inhibited the ability of H295R cells to form clones to a significantly greater extent than dxr alone (p < 0.05) (Fig. 4c) . This effect was also observed in 3D cultures on the formation of H295R spheroids on which P375 enhanced dxr efficiency by about 2 times (Supporting Information Fig. S4 ).
Methiothepin inhibits doxorubicin efflux from ACC cells
As in the yeast assay, epifluorescence microscopy was used to measure the effect of P375 on dxr efflux on H295R cells. As exemplified in Figure 5a , incubation of cells with dxr induced a strong accumulation of dxr in the nuclei. The intracellular dxr amount was drastically reduced after 30 min of incubation with the efflux buffer. Quantification of this observation indicated that 60-70% of dxr was transported out of cells over this time period. The presence of P375 in the efflux buffer allowed retaining of about 60% of cellular dxr. This finding demonstrated that, in H295R cells as in Patched expressing yeast, P375 strongly inhibits the efflux of dxr. Interestingly, the P-gp antagonist PSC833 had no effect on dxr efflux despite the fact that P-gp is expressed in ACC cells (Fig. 5d) . However, we observed that PSC833 inhibited Hoechst efflux in contrast to P375 (Fig. 5b) . These results suggest that P375 inhibits specifically dxr efflux and that Patched strongly contributes to dxr efflux in this model. Moreover, the depletion by 60% of Patched protein in H295R cells using a specific siRNAs equally reduced dxr efflux by 60%, confirming that Patched is the major dxr efflux pump in these cells (Fig. 5c ). This is in good agreement with experiments showing that a 70% decrease in Pgp expression using a specific siRNA inhibited only about 10% of the dxr efflux (Fig. 5d) , which corroborates that P-gp does not contribute significantly to dxr efflux in these ACC cells.
Methiothepin inhibits doxorubicin efflux and increases doxorubicin cytotoxicity on other cancer cells expressing Patched
The effect P375 was also tested on other human cancer cell lines endogenously overexpressing Patched, such as the colorectal carcinoma cell line HCT116, the breast adenocarcinoma cell line MCF7 and the melanoma cell line A375 (Supporting Information Fig. S5a) . We observed that P375 significantly inhibited dxr efflux (Supporting Information Fig.  S5b) , and strongly increased the cytotoxicity of dxr (Supporting Information Fig. S5c ) on these three cell lines. P375 might therefore be of general interest for the development of cancer therapy strategies that rely on the combination of Patched inhibitors with dxr. This will be illustrated below for the example of ACC.
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Methiothepin profiling and pharmacokinetics parameters
As summarized in Supporting Information Table S1 , profiling data indicated that P375 is a particularly stable lipophilic compound. The metabolic stability of P375 was confirmed in vivo in a pharmacokinetic (PK) study, which was conducted on male ICR mice following a single intravenous (IV) or oral (PO) administration of P375 (Supporting Information  Table S2 ).
Methiothepin enhances doxorubicin efficacy in vivo
Short-and long-term therapeutic efficacy of P375, dxr or a combination of both compounds was investigated in H295R xenograft bearing mice. In our study, liposomal dxr (lipdxr) was preferred over dxr because of its higher effectiveness in this model. 33 After administration of one therapeutic cycle, the quantification of apoptotic cells in tumors showed significant antitumoral efficacy exclusively for P375 1 lipdxr treatment (61.6 6 19.7 apoptotic cells/mm 2 vs. 16.4 6 4.0 apoptotic cells/mm 2 in control mice, p < 0.05; Fig. 6a ). Moreover, epifluorescence images taken from tumor slides revealed that the amount of dxr in tumors from mice treated with lipdxr and P375 was significantly higher to the amount of dxr in tumors from mice treated with lipdxr alone (Fig. 6b) .
For long-term treatment, two drug cycles were administered with a therapy-free interval of 6 days in between. Primary endpoint of our study was tumor size (expressed as length 3 width in cm 2 ). This experiment confirmed the previously indicated higher therapeutic efficacy for the combined administration of P375 1 lipdxr (p < 0.01 vs. controls on Day 39; Fig. 6c) , without any obvious signs of undesirable side effects such as weight loss or abnormal behavior of the animals. Epifluorescence images taken from tumor slides showed that P375 enhanced significantly (about 3 times) the dxr content in tumors (Fig. 6d  left) , which corroborated the results obtained from the shortterm experiment and was in very good agreement with in vitro studies. Interestingly, epifluorescence images from heart slides . P375 enhances the pro-apoptotic, anti-proliferative and anti-clonogenic effect of doxorubicin. (a) Cell apoptosis was evaluated using the luminescent assay Caspase-Glo 3/7 after 48 hr treatment with medium alone or with medium containing dxr alone, P375 alone or dxr and P375 together. Histograms represent the mean 6 SEM of three independent experiments and data were analyzed using ANOVA multiple comparison test and Bonferroni correction. Significance is attained at p < 0.05 (*) (**p < 0.005, ***p < 0.0005). (b) For proliferation tests, cells were seeded in 96-well plates and treated with medium containing serial dilutions of dxr in the presence or the absence of P375. After 7 days, Neutral Red was used for quantification of living cells. Data are represented as mean 6 SEM. IC50 were calculated from the mean of at least three independent experiments using Prism6 software. (c) For clone formation tests, cells were seeded in 24-well plates and treated with DMSO as control, dxr alone, P375 alone or a combination of dxr and P375. After 14 days, clones were revealed with crystal violet solution, pictures were taken and absorbance was read at 550 nm after solubilization. Histograms represent the mean 6 SEM of at least three independent experiments for each cell line and were analyzed using ANOVA multiple comparison test and Bonferroni correction. Significance is attained at p < 0.05 (*) (***p < 0.0005). [Color figure can be viewed at wileyonlinelibrary.com]
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Hasanovic et al. Images were acquired with a fluorescence microscope using a 403 objective. Dxr or Hoechst fluorescence was quantified using ImageJ software for about 100 cells per condition per experiment. Patched, P-gp and b-tubulin signals were also quantified using ImageJ software. All data presented are the mean 6 SEM of three independent experiments and were analyzed using ANOVA multiple comparison test and Bonferroni correction. Significance is attained at p < 0.05 (*).
showed that P375 did not increase the amounts of dxr in murine hearts (Fig. 6d right) .
Discussion
In our study, we show that the Hedgehog receptor Patched is expressed in adrenocortical carcinoma patients, and is a major player of the doxorubicin (drx) efflux and the dxr resistance in the human ACC cell line H295R. We demonstrate that methiothepin (P375) significantly enhances the cytotoxic, pro-apoptotic, anti-proliferative and anticlonogenic effects of dxr on ACC cells by inhibiting the dxr efflux activity of Patched. In vivo experiments performed on Figure 6 . P375 enhances the efficiency of doxorubicin on H295R tumor bearing mice. (a) Quantification of TUNEL positive cells in tumor slides after one therapeutic cycle. Stars denote significant differences compared to controls. (b) Dxr quantification in mice tumors after one therapeutic cycle was performed using fluorescence microscopy analysis of tissue slides and ImageJ software. Data presented are mean 6 SEM and were analyzed using Student's t-test. Significance is attained at p < 0.05 (*). (c) Evolution of the tumor size for the four groups of mice treated with two therapeutic cycles with different treatment modalities. The two-way repeated measures ANOVA analysis showed a significant difference between the group control and the group treated with P375 and lipdxr. (d) Dxr in mice tumors and hearts after two therapeutic cycles was quantified using fluorescence microscopy analysis of tissue slides and ImageJ software. Data presented are mean 6 SEM and were analyzed using Student's t-test. Significance is attained at p < 0.05 (*) (**p < 0.005). [Color figure can be viewed at wileyonlinelibrary.com] mice bearing human ACC cells (H295R) xenografts showed that the addition of methiothepin to liposomal dxr treatment inhibited tumor growth more significantly than liposomal dxr alone by enhancing dxr accumulation in tumors. Notably, these effects were achieved without obvious undesirable side effect and specifically, without increasing the amounts of dxr in heart tissues of treated animals.
Overall, these findings are especially interesting as dxr is one of the three chemotherapeutic agents included in the gold standard ACC therapy and since Patched was found to be expressed in ACC tumor samples from our cohort. Of note, the standard therapy composed of dxr in combination with etoposide, cisplatin and mitotane (EDP-M) has many side effects and often fails due to resistance to the treatment causing a poor overall patient survival. 28, 29, 34 Methiothepin is a small molecule known as a nonselective 5-HT receptor antagonist with antipsychotic activity. [35] [36] [37] Three chlorinated derivatives Clorotepine, Zotepine and Clotiapine are antipsychotics drugs marketed for the treatment of schizophrenia. 38 We showed that these drugs also enhanced the doxorubicin cytotoxicity on ACC cells but with lower efficacy than methiothepin (IC50 of 15 mM, 17 mM and 12 mM, respectively) (Supporting Information Fig.  S6 ). This kind of poly-pharmacology profile has been observed for many drugs, probably because of the broad spectrum of molecules capable of being transported by multidrug transporters. For instance, HIV-protease inhibitors like saquinavir or its NO-derivatives have been shown to increase sensitivity to chemotherapy by inhibiting ABC transporters. 39 However, our results show that methiothepin does not inhibit ABC transporters like P-gp but interacts specifically with Patched.
Profiling data and pharmacokinetics study indicate that methiothepin possesses excellent drug-like properties, with a particularly favorable metabolic stability.
Altogether, results position methiothepin favorably as a drug-like molecule. Therefore, our study strongly suggests that ACC patients with tumors expressing Patched might benefit from therapies based on the use of methiothepin or one of its analogs in combination with dxr, either alone or as part of the standard therapy formulation EDP-M.
Dxr has been in use for over five decades as the backbone of chemotherapy treatment regimens for a wide range of cancers. However, due to heart failure, the maximum life time cumulative dose of dxr has been limited decreasing the benefits that patients may receive from this potent drug. 40 Since methiothepin strongly increases dxr efficiency and specifically inhibits Patched dxr efflux in cancer cells, the effective dose of dxr received by patients could be reduced inducing less impairment in cardiac function. Moreover, our in vivo studies showed that methiothepin enhanced liposomal dxr (commercialized as Caelyx or Doxil) which is a new formulation of dxr approved by FDA for cancer therapy. The ability of liposomal dxr to buffer a number of undesirable side effects of dxr, including a major risk reduction in cardiac toxicity, is now well established 41 and should strengthen the consideration to further studying the use of a combination of methiothepin and liposomal dxr for Patched expressing cancers treatment.
Interestingly, the present work also brings evidences that dxr efflux in the ACC cell line H295R mainly occurs through Patched and not through ABC transporters such as P-gp. This is in good agreement with previous work suggesting that dxr resistance in human adrenocortical and renal carcinomas is mediated by mechanisms other than P-gp. 42 Patched is not part of the ABC transporters family. Indeed, we previously showed that Patched uses the proton motive force to efflux drugs similarly to the bacterial efflux pumps from the RND family. 6 This may seem surprising; however, the alteration of energy metabolism that occurs in hypoxic conditions in cancer cells has been shown to lead to lactate accumulation and intracellular acidification. [43] [44] [45] Accordingly, rapidly dividing cancer cells produce and release large amounts of protons into the extracellular compartment due to enhanced glucose utilization. This pattern of acidic extracellular environment and the alkaline cytosol is considered a hallmark of malignant cancers and is referred to as a "reversed pH gradient." 46 Therefore, in cancer cells, Patched can function as an efflux pump using the proton gradient. This makes Patched a particularly relevant therapeutic target for recurrent and metastatic cancers such as ACC, and Patched drug efflux inhibitors potentially represent much more cancer specific and less toxic therapeutics than ABC transporters antagonists.
Moreover, experiments which show that methiothepin is also able to inhibit dxr efflux and increase dxr cytotoxicity on colorectal, breast and melanoma cancer cells endogenously overexpressing Patched suggest that Patched drug efflux inhibition could improve the efficiency of dxr not only on ACC, but also on a panel of Patched-expressing cancers.
In conclusion, our results provide a proof of concept that the combination of dxr with a Patched drug efflux inhibitor could significantly improve the therapeutic treatment of ACC, and most likely also of other Patched-expressing cancers including melanoma, breast and colorectal cancers.
